Destiny Hinton

Scientists at St. Jude are leading the way on understanding cancer predisposition and the way that inherited genetics can inform patient care.

Scientists at St. Jude Children’s Research Hospital are deploying genomic technologies to hunt for vulnerabilities in cancer.

Participants in the St. Jude HPV Cancer Prevention Program’s HPV Cancer Survivors School are using their powerful voices to advocate for HPV vaccination during January which is Cervical Cancer Awareness Month.

St. Jude Children’s Research Hospital has a rich history of research on genetics stemming from the Pediatric Cancer Genome Project and reverberating through laboratories today.

Sometimes a scientist’s next step isn’t a step, but more of a career-defining leap. Early-career investigator Lily Guenther, MD, shares her experience of taking that leap and starting a laboratory at St. Jude.

St. Jude computational biologists created a computational score predicting cancer drug sensitivity to HDAC6 inhibitors in a promising phase Ib clinical trial.

St. Jude received the hospital’s first expanded access designation from the FDA for use of PET scans with [11C]Methionine a tracer that makes imaging results clearer.

St. Jude scientists have learned that bacteria are more successful at developing antibiotic resistance when they swap genes through recombination.

The St. Jude Methodist Sickle Cell Disease Transition Clinic helps patients move from pediatric to adult care, an important stage where patients often experience roadblocks to maintaining their health.

A St. Jude clinical trial launched more than 25 years ago has helped to transform understanding and care for children with the brain tumor craniopharyngioma.